Agios Pharmaceuticals, Inc.
AGIO
$27.42
-$0.07-0.26%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 43.69% | 44.57% | 6.56% | 51.06% | 21.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 43.69% | 44.57% | 6.56% | 51.06% | 21.15% |
| Cost of Revenue | 20.80% | 18.69% | 6.62% | 7.68% | -11.20% |
| Gross Profit | -17.61% | -15.52% | -6.62% | -3.34% | 14.39% |
| SG&A Expenses | 7.10% | 29.08% | 33.90% | 46.43% | 49.24% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.08% | 21.92% | 15.05% | 19.75% | 3.21% |
| Operating Income | -13.67% | -20.07% | -15.81% | -17.65% | -1.90% |
| Income Before Tax | -110.33% | -16.54% | -9.49% | -9.86% | 1,196.14% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -110.91% | -16.54% | -9.49% | -0.61% | 1,137.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -110.91% | -16.54% | -9.49% | -0.61% | 1,137.97% |
| EBIT | -13.67% | -20.07% | -15.81% | -17.65% | -1.90% |
| EBITDA | -13.83% | -20.70% | -16.12% | -17.92% | -2.21% |
| EPS Basic | -110.69% | -14.27% | -7.45% | 1.46% | 1,117.28% |
| Normalized Basic EPS | -14.98% | -14.27% | -7.43% | -7.59% | 5.46% |
| EPS Diluted | -110.97% | -14.27% | -7.45% | 1.67% | 1,089.02% |
| Normalized Diluted EPS | -18.00% | -14.27% | -7.43% | -7.59% | 7.87% |
| Average Basic Shares Outstanding | 2.11% | 1.99% | 1.91% | 2.10% | 2.04% |
| Average Diluted Shares Outstanding | -0.50% | 1.99% | 1.91% | 2.10% | 4.71% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |